|

Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance

RECRUITINGN/ASponsored by Hellenic Mediterranean University
Actively Recruiting
PhaseN/A
SponsorHellenic Mediterranean University
Started2026-03-30
Est. completion2028-03-30
Eligibility
Age30 Years – 65 Years
Healthy vol.Accepted

Summary

This study investigates how weight-loss medications, specifically GLP-1 receptor agonists, affect body composition, with a special focus on preserving muscle mass in adults with obesity. While these medications are highly effective for weight loss, they can sometimes lead to an unwanted loss of valuable muscle mass (a condition that can lead to sarcopenia). To explore how to prevent this, researchers are conducting a 3- to 6-month randomized controlled trial involving adults aged 30 to 65 years with a BMI greater than 30 kg/m². Participants who are receiving GLP-1 medications will be randomly assigned to one of two groups: one group will receive the standard medication treatment alone, while the other group will receive the medication along with specific dietary guidance focused on increasing daily protein intake.

Eligibility

Age: 30 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults 30-65 years old
* BMI: ≥30 kg/m²
* Signed Informed Consent

Exclusion Criteria:

A. Metabolic and Medical Conditions:

* Uncontrolled type 2 diabetes (HbA1c \> 9.0%)
* Known cardiovascular disease (e.g., coronary artery disease, heart failure NYHA 3-4)
* Chronic kidney disease stage 4-5 (GFR \<60 ml/min)
* Liver disease (known hepatitis, ALT ≥ 3 or total bilirubin ≥ 2 times ULN)
* Inflammatory bowel disease
* Celiac disease
* History of pancreatitis
* Any disorder potentially causing malabsorption
* Active cancer or history of malignancy within the past 3 years
* Psychiatric disorders affecting adherence or assessment B. Medication and Supplement Use
* Chronic use of medications affecting metabolism or body composition (e.g., corticosteroids, anti-obesity drugs)
* Use of anti-inflammatory or antioxidant medications
* Use of probiotics, prebiotics, or laxatives within the last month
* Unstable medication regimen (changes within the past 3 months)
* Use of protein and creatine supplements.

C. Dietary and Lifestyle Factors:

* Alcohol or substance abuse
* Engagement in intense regular physical activity

D. Reproductive Status:

* Pregnancy or breastfeeding
* Pregnancy within the past 12 months
* Plans to become pregnant during the study

E. Other:

\- Any condition that, in the opinion of the Investigator, may interfere with participation, adherence, or the interpretation of study results.

Conditions2

ObesityWeight Loss

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.